Loading clinical trials...

Blood Screening for Adult Colorectal Cancer | Clinical Trials | Clareo Health

RECRUITING

Blood Screening for Adult Colorectal Cancer

Evaluation of the Discriminatory Role of Blood TFPI-1 and TFPI-2 in Adult Colorectal Cancer

NCT05577143•University Hospital, Lille

Summary

Multicenter, inter-regional, case-control study with the primary objective of evaluating the discriminative power of the blood biomarker TFPI-1 to separate patients with histologically proven CRC from an asymptomatic control population between 50 and 75 years of age with normal colonoscopy.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with suspected colorectal cancer for which colonoscopy is indicated.
•Patients between 50 and 75 years old, asymptomatic from the digestive point of view (for example referred for colonoscopy as part of a pre-operative check-up of an inguinal hernia or 3 months after an episode of complicated sigmoiditis), for whom a follow-up colonoscopy is indicated.
•Note.
•If the post-inclusion colonoscopy is normal, no biopsy will be performed and patients will be assigned to the control group.
•If the colonoscopy performed after inclusion is abnormal (presence of at least one mucosal lesion), patients will be assigned to the "colorectal cancer" group or to the "polyps" group depending on the results of the anatomopathological analysis of the lesion(s)

Exclusion Criteria

•All clinical situations outside of CRC that could increase TFPI-1 or 2 blood levels: acute coronary syndrome (unstable angina, acute myocardial infarction), severe sepsis, decompensated cirrhosis, pregnancy, chronic inflammatory bowel disease (Crohn's or ulcerative colitis), colitis or radiation rectitis.
•Endoscopic polypectomy without prior histological confirmation.
•Emergency (occlusion or peritonitis)
•Minor patients.
•Persons of full age under legal protection or unable to express their consent
•Persons not affiliated to a social security system or beneficiaries of such a system.
•Pregnant women, women in labor or nursing mothers.

Locations (1)

Hôpital HURIEZ - Chirurgie digestive et transplantation

Lille, France

Key Dates

Start Date

March 23, 2023

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

December 26, 2025

Enrollment

303

ESTIMATED participants

Conditions

Cancer Colorectal

Contacts

Philippe ZERBIB, MD,PhD

CONTACT

0320445962 philippe.zerbib@chru-lille.fr

Postoperative Exercise Training and Colorectal Cancer Liver Metastasis

NCT05579340

Cancer Metastatic to LiverCancer Colorectal

View study

COMPLETEDNA

Impact of a Patient Decision Aid Intervention

NCT05573022

Cancer, BreastCancer Colorectal

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 26, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Blood Screening for Adult Colorectal Cancer

Inclusion Criteria

Exclusion Criteria

Postoperative Exercise Training and Colorectal Cancer Liver Metastasis

Impact of a Patient Decision Aid Intervention

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study

Impact of EDUcation Strategy on Patients With COLorectal CANCER or Advanced Adenoma in the Detection of Colorectal Cancer of Their First-degree Relatives